Hasil Pencarian  ::  Simpan CSV :: Kembali

"Data epidemiologi menunjukkan bahwa dari semua keganasan tiroid, sekitar 80% hingga 85% di antaranya adalah karsinoma tiroid papiler (KTP). Biomarker untuk memprediksi metastasis KGB leher kini mulai banyak diteliti pada pasien KTP seperti matrix metalloproteinase (MMP) dan vascular endothelial growth factor (VEGF). Meskipun belum terdapat kesepakatan diagnostik terhadap MMP-9 dan VEGF-C sebagai prediktor metastasis KGB pada KTP, beberapa studi telah menunjukkan hubungan keduanya terhadap metastasis KGB. Penelitian ini bertujuan untuk mengetahui hubungan antara MMP-9 dengan VEGF-C pada metastasis KGB leher pada pasien KTP. Peneliti melakukan studi desain potong lintang di RSUPN Cipto Mangunkusumo, Jakarta Pusat. Pasien yang terdiagnosis KTP berdasarkan pemeriksaan histopatologi diinklusi dalam penelitian ini. Pasien yang telah terbukti memiliki metastasis jauh dan data tidak lengkap dieksklusi dalam penelitian. Ekspresi MMP-9 dan VEGF-C diteliti di Laboratorium Patologi Anatomi FKUI/RSCM. Sebanyak 62 pasien diinklusi dalam penelitian ini, dengan proporsi 80,6% perempuan dan 19,4% laki-laki. Ekspresi MMP-9 ditemukan lebih tinggi pada kelompok metastasis (p<0,001). Hal yang sama juga terjadi pada perbedaan median ekspresi VEGF-C, yang mana median ekspresi penanda ini pada kelompok metastasis lebih tinggi dibandingkan non-metastasis (p<0,001). Peneliti menemukan bahwa terdapat korelasi positif dan bermakna antara H-score MMP-9 dan VEGF-C, dengan koefisien korelasi 0,618. Terdapat hubungan yang bermakna antara ekspresi MMP-9 dan VEGF-C dengan kejadian metastasis KGB leher pada pasien KTP. Ekspresi MMP-9 dan VEGF-C ditemukan lebih tinggi pada kelompok metastasis. Peningkatan ekspresi MMP-9 juga berkorelasi positif dengan peningkatan ekspresi VEGF-C. ......Approximately 80% to 85% of thyroid malignancies were papillary thyroid carcinoma (PTC). Biomarkers to predict cervical lymph node metastases have now begun to be widely studied in PTC patients, such as matrix metalloproteinase (MMP) and vascular endothelial growth factor (VEGF). Although there was no diagnostic agreement on MMP-9 and VEGF-C as predictors of lymph node metastasis in PTC, several studies have shown an association between the two for lymph node metastasis. This study aims to determine the relationship between MMP-9 and VEGF-C in cervical lymph node metastases in PTC patients. A cross-sectional design study was conducted at Cipto Mangunkusumo General Hospital, Jakarta. Patients diagnosed with PTC based on histopathological examination were included in this study. Patients with distant metastases were excluded from the study. The expression of MMP-9 and VEGF-C was investigated at the Anatomical Pathology Laboratory FKUI/RSCM. A total of 62 patients were included in this study, with 80.6% female and 19.4% male. The MMP-9 expression was found to be higher the metastatic group (p<0.001). The same results were also found in VEGF-C expression, where the median expression of this marker in the metastatic group was higher than the non-metastatic group (p<0.001). We found a significant and positive correlation between the H-score of MMP-9 and VEGF-C (correlation coefficient of 0.618). There is a significant relationship between the expression of MMP-9 and VEGF-C with the cervical lymph node metastases in PTC patients. The MMP-9 and VEGF-C expression was higher in the metastatic group. The increased MMP-9 expression is also positively correlated with increased VEGF-C expression."

"Latar belakang: CTC sebagai bagian dari liquid biopsy berperan dalam melakukan monitoring pasien kanker payudara yang menjalani terapi. Adanya CTC menjadi pertanda resistensi terapi dan memengaruhi prognosis pasien. Penelitian ini bertujuan melihat adakah perubahan nilai CTC pada pasien kanker payudara stadium lokal lanjut atau lanjut yang mendapatkan kemoterapi serta melihat perubahan nilai CTC tersebut apakah dipengaruhi oleh usia, status menopause, subtipe, metastasis, dan grade.Metode: Didapatkan 30 sampel pasien kanker payudara stadium lokal lanjut atau lanjut yang akan mendapatkan kemoterapi berbasis Anthracycline dan Taxan. Pre kemoterapi pasien diambil darah perifer dan dilakukan pemeriksaan CTC menggunakan flowcytometry dengan antibodi EpCAM. Pasien lalu menjalani siklus kemoterapi hingga lengkap. Setelah itu pasien kembali diambil darah perifer dan diperiksa nilai CTC post kemoterapi.Hasil: Dari ke 30 sampel, didapatkan mean usia 47,93+7.30. Sebanyak 56,7 (n=17) belum menopause, 43,3% status tumor T3 dan T4, status kelenjar getah bening terbanyak adalah N0 dan N1 (43,3%). Hanya 2 pasien yang ditemukan ada metastasis. 56,7% pasien dengan grade 3, dan subtipe terbanyak adalah luminal B ( 63,4%, n=19). Terdapat 22 pasien (73,3%) dengan ER positif, 14 pasien (46,7%) dengan PR positif. Terdapat 11 pasien (36,7%) dengan Her2 positif dan 21 pasien (70%) dengan Ki67 high proliferation. Hasil CTC pre kemoterapi didapatkan nilai median 1460,50 sedangkan CTC post kemoterapi didapatkan nilai median 415,50 dilakukan uji Wilcoxon dan perbedaan bermakna dengan nilai p=0,002. Analisis multivariat regresi linier dihubungkan antara penurunan nilai CTC terhadap usia, status menopause, subtipe, metastasis, dan grading didapatkan status menopause berhubungan bermakna terhadap perubahan nilai CTC (p<0,05).Kesimpulan: CTC pada pasien kanker payudara stadium lokal lanjut dan lanjut setelah kemoterapi lebih rendah bermakna dibandingkan sebelum kemoterapi. Status menopause memiliki hubungan bermakna terhadap penurunan jumlah CTC setelah kemoterapi pada kanker payudara stadium lokal lanjut dan lanjut.......Background: As part of liquid biopsy, CTCs play a role in monitoring breast cancer patients undergoing therapy. The existence of CTCs is a sign of therapy resistance and affects patient prognosis. This study aims to examine whether there are changes in CTC values in patients with locally advanced or advanced breast cancer, who receive chemotherapy and are influenced by age, menopause status, subtype, metastasis, and grade.Method: Of the 30 samples of locally advanced or advanced breast cancer patients receiving Anthracycline and Taxan-based chemotherapy were obtained. Pre-chemotherapy, peripheral blood, was drawn and CTCs were examined using flow cytometry with EpCAM antibody. Patients then undergo a complete chemotherapy cycle. After that, the patients were again taken peripheral blood and examined for post-chemotherapy CTC values.Result: The study was conducted at Cipto Mangunkusumo Hospital, started from December 2022 to December 2023. Of the 30 samples with the mean age was 47,93+7,30. A total of 56,7 (n=17) were not menopause, 43,3% of tumor status with the T3 and T4, and the most common lymph node status with the N0 and N1 (43,3%). Only two patients were found to have metastasis. Then, 56,7% of patients had grade 3, and the most common subtype was luminal B (63,4%, n=19). There were 22 patients (73,3%) with ER positive, 14 patients (46,7%) with PR positive, 11 patients (36,7%) with Her2 positive, and 21 patients (70%) with Ki67 high proliferation. Pre-chemotherapy CTC results obtained a median value of 1460.50, Meanwhile, post-chemotherapy CTC obtained a median value of 415,50. Wilcoxon test was performed and the difference was significant with a value of p = 0,002. Multivariate linear regression analysis was correlated between the decrease in CTC values with age, menopause status, subtype, metastasis, and grading. The menopausal status has a significant association with decrease CTC values (p<0,05).Conclusion: CTC in locally advanced and advanced breast cancer patients after chemotherapy was significantly lower than before chemotherapy. menopause status has a significant association with decreased CTC values after chemotherapy in locally advanced and advanced breast cancer."